Other relevant Information

GRIFOLS, S.A. guarantees that the texts published in this page correspond exactly and entirely with the texts sent to the CNMV by the Company or by third parties. All the communications are available in the Web page of the CNMV.

2021

Grifols and GIC obtain authorization for their strategic agreement for USD 1 billion Grifols closes its EUR 2 billion bond issuance to finance its investment in Biotest Grifols initiate the launch of a €2bn equivalent senior unsecured notes Consent solicitation results on the lenders under Credit Agreement and the European Investment Bank to amend certain provisions of the senior debt Consent solicitation results on Secured and Unsecured Notes to amend certain provisions of the senior debt Commencing a consent solicitation to amend certain provisions of the senior debt Grifols signs an agreement with ImmunoTek to open 21 plasma centers and further advances on its expansion plan Grifols announces a strategic investment from GIC of USD 1 billion Termination of the buyback programme Recurring information under the buy-back programme of shares Recurring information under the buy-back programme of shares Information on the specific dividend payment conditions Recurring information under the buy-back programme of shares Information on the resolutions approved at the General Meeting of Shareholders on May 21, 2021 Recurring information under the buy-back programme of shares Recurring information under the buy-back programme of shares Recurring information under the buy-back programme of shares Recurring information under the buy-back programme of shares Recurring information under the buy-back programme of shares Notice of Annual General Shareholders' Meeting 2021 Recurring information under the buy-back programme of shares Grifols advances in the execution of its expansion plan with the acquisition of 7 plasma centers in the U.S. Recurring information under the buy-back programme of shares Recurring information under the buy-back programme of shares Recurring information under the buy-back programme of shares Buy-back plan of shares Grifols reinforces its innovation strategy after completing the acquisition of GigaGen Grifols acquires 25 U.S.-based plasma centers from BPL ensuring one million additional liters for fractionation The Regulations of the Sustainability Committee Grifols begins a new COVID-19 trial containing anti-SARS-CoV-2 polyclonal antibodies